Screening of compounds for ADME, toxicity and efficacy parameters
Research type
Research Study
Full title
Screening of research compounds to characterise the compounds for ADME (absorption, distribution, metabolism and excretion), toxicity parameters and efficacy against drug targets which are key properties to evaluate when developing successful, safe and effective drugs.
IRAS ID
169413
Contact name
Laura K Hinton
Contact email
Sponsor organisation
Cyprotex
Duration of Study in the UK
10 years, 1 months, 6 days
Research summary
Cyprotex specialises in ADME-Tox and efficacy screening including both in vitro (laboratory experiments) and in silico (computer modelling) approaches. Cyprotex serves the Pharmaceutical and Biotech, Cosmetics/Personal Care and Chemicals Industries as well as academia and not-for-profit organisations.
ADME-Tox and efficacy is a collective science that studies how a potential drug or toxin is Absorbed into the body, Distributed through the body, Metabolised (changed by body enzymes into different molecular entities), by what routes it is Excreted, and whether it has a potential to cause Toxicity and exert its effect (efficacy). Hence the acronym, ‘ADME Tox’ or ‘ADMET’ and efficacy.
For example, most drugs need to be delivered in pill form. Pills must be absorbed in the intestine in order to enter the blood stream. This is part of the Absorption part of ADME Tox. Cyprotex's proprietary in silico absorption model can predict whether a proposed drug will be absorbed in the human intestine. ‘In silico’, means a software model of how the body acts. Our in vitro permeability assays can determine whether a drug will be absorbed in the intestine. ‘In vitro’ means a test-tube based experiment involving potential new drugs and cells.
This study is ongoing support for companies developing and testing of new research compounds and as such has no end date. Research compounds are typically new drugs in development and chemicals which may result in human exposure.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
14/EM/1298
Date of REC Opinion
19 Jan 2015
REC opinion
Further Information Favourable Opinion